Revealing Results of Phase Three Randomized NETTER-2 Novartis Trial to Explore a First Line Treatment for NET

Time: 9:15 am
day: Conference Day One


  • To discuss the results of the NETTER 2 clinical trial
  • To review the current use of RLT in first line treatment of cancer
  • To understand the role of RLT in aggressive NET disease